Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities
NEW YORK, Oct. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p01009664/Global-Markets-for-Treatments-of-Dementia-and-Movement-Disorders----Focus-on-Progressive-Dementia-with-Other-Neurological-Abnormalities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
INTRODUCTION
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders. The key objective is to present a comprehensive analysis and the future direction of the market as it shapes drug and therapy development.
This report explores present and future strategies within the neurodegenerative disorder market, which includes treatments and therapies for progressive dementia, progressive dementia with other neurological abnormalities and movement disorders. Market gains, setbacks and needs are discussed in this report. Comparisons, usage and the advantages and disadvantages of different types of technologies, including small molecules and monoclonal antibodies, are also presented in this report.
A detailed analysis of the structure of the syndromes of dementia and movement disorder industry has been conducted. Revenues are broken down by neurodegenerative disease and primary clinical/pathological feature. Sales figures are estimated for the five-year period from 2012 through 2017.
Applications for syndromes of dementia and movement disorder treatments, or therapeutic technologies, are also discussed separately in the report, with an emphasis on small molecule and monoclonal antibodies technology. The report also covers significant patents and their allotment in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of syndromes of dementia and movement disorders and company collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technological developments are providing disease-modifying therapies for the late stages of the disorders. Collaborations between research institutes and pharmaceutical companies are on the rise as state-of-the-art technology is being explored to develop more efficient products and therapies.
R&D spending, along with increasing competition, patent expiries and new technologies are taking the market in a new direction. Global market revenues increased from 2009 to 2011 and are expected to continue to show growth over the forecast period as new advances, launches and collaborations continue to influence the market. This study looks at most of the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type of technology in light of the new technologies, growing competition and changing customer needs.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth in treatments for Alzheimer's disease, Lewy body dementia, Pick's disease, Huntington's disease, corticobasal ganglionic degeneration, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians will find this study to be of interest.
SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.
METHODOLOGY
BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of enzyme inhibitors' technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
ABOUT THE AUTHOR
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this study is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.
Some of her other reports with BCC include Reagents for Chromatography; Spectroscopy—An Enduring Market; Advanced Drug Delivery Systems—Technologies and Global Markets; Orthopedic Drugs, Implants and Devices—Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry—The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging—Global Markets; Chiral Technology—Global Markets; Autacoids and Related Drugs—Technologies and Global Markets; Contraceptives—Technologies and Global Markets; Liver Disease Treatments—The Global Market; Hormone Replacement Therapies and Other Hormone Therapies—Global Markets; Cardiovascular Medicine—Diagnostics, Drugs and Devices; and Cancer Therapies ? Technologies and Global Markets.
The lead consultant on this project is Ms. Ruma Chakravarty, who holds a master's degree in biophysics. She has tremendous experience in market research, quality, process improvement and lean and six sigma concepts.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 1
STUDY OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
CONTRIBUTIONS OF THE STUDY AND FOR WHOM 1
SCOPE OF THE STUDY 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 2
RELATED BCC RESEARCH REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER 2 EXECUTIVE SUMMARY 5
SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 6
CHAPTER 3 OVERVIEW 8
THE BRAIN 8
CEREBRAL CORTEX 8
BRAIN STEM 9
SPINAL CORD 10
NEUROTRANSMITTERS 11
CLASSIFICATION OF NEURODEGENERATIVE DISORDERS 11
TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY
PRIMARY CLINICAL/PATHOLOGICAL FEATURE 11
NEURODEGENERATIVE DISORDERS 12
ALZHEIMER'S DISEASE 12
LEWY BODY DEMENTIA 12
PICK'S DISEASE 13
HUNTINGTON'S DISEASE 13
CORTICAL BASAL GANGLIONIC DEGENERATION 13
PARKINSON'S DISEASE 14
MULTIPLE SYSTEM ATROPHY 14
PROGRESSIVE SUPRANUCLEAR PALSY 14
HALLERVORDEN-SPATZ DISEASE 15
DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS 15
DIAGNOSTIC TESTS FOR PARKINSON'S 15
DIAGNOSTIC TESTS FOR ALZHEIMER'S 16
DIAGNOSTIC TESTS FOR PICK'S DISEASE 16
DIAGNOSTIC TESTS FOR MULTIPLE SYSTEM ATROPHY 16
DIAGNOSTIC TESTS FOR PROGRESSIVE SUPRANUCLEAR PALSY 16
DIAGNOSTIC TESTS FOR CORTICAL BASAL GANGLIONIC DEGENERATION 17
DIAGNOSTIC TESTS FOR LEWY BODY DEMENTIA 17
DIAGNOSTIC TESTS FOR HALLERVORDEN-SPATZ DISEASE 17
CHAPTER 4 REGULATORY ASPECTS 19
INTRODUCTION 19
DRUG APPROVALS 19
TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012 20
TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS 22
TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012 22
TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, 2010 TO MARCH 2012 23
REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDER PRODUCTS 23
CHAPTER 5 NEW DEVELOPMENTS 25
TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2012 25
TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2011 30
TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010 39
CHAPTER 6 GLOBAL MARKETS 45
MARKETS BY CLINICAL/PATHOLOGICAL FEATURE 45
MARKET OVERVIEW 45
MARKET REVENUES 46
TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 46
FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 47
MARKET SHARE 47
TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT
NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47
FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT
NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47
MARKET BY DISEASE TYPE 48
MARKET OVERVIEW 49
MARKET REVENUES 50
TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR
NEURODEGENERATIVE DISORDERS, THROUGH 2017 ($ MILLIONS) 50
FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR
NEURODEGENERATIVE DISORDERS, 2010-2017 ($ MILLIONS) 50
MARKET SHARE 51
TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%) 51
FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%) 52
MARKET BY REGION 52
MARKET OVERVIEW 52
MARKET REVENUE 53
TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 ($ MILLIONS) 53
FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017 ($ MILLIONS) 53
MARKET SHARE 54
TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54
FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54
MARKETS BY TECHNOLOGY 54
MARKET OVERVIEW 55
MARKET REVENUE 55
TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 56
FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 56
MARKET SHARE 56
TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57
FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57
CHAPTER 7 MARKET FOR DRUGS TO TREAT PROGRESSIVE DEMENTIA WITH OTHER
NEUROLOGICAL ABNORMALITIES 59
MARKET BY DISEASE TYPE 59
HUNTINGTON'S DISEASE 59
CORTICOBASAL GANGLIONIC DEGENERATION 60
MARKET OVERVIEW 60
TABLE 17 CHDI FOUNDATIONS' KEY DEVELOPMENTS IN TREATING HUNTINGTON'S
DISEASE 61
MARKET REVENUE 62
TABLE 18 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017 ($
MILLIONS)
62
FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017 ($
MILLIONS)
63
MARKET SHARE 63
TABLE 19 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63
FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63
MARKET BY REGION 64
MARKET OVERVIEW 64
TABLE 20 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017 ($ MILLIONS) 65
FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017 ($ MILLIONS) 65
MARKET SHARE 66
TABLE 21 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66
FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66
REGIONAL MARKETS BY DISEASE TYPE 66
HUNTINGTON’S DISEASE 66
TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE
BY REGION, THROUGH 2017 ($ MILLIONS) 67
FIGURE 13 GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE BY
REGION, 2010-2017 ($ MILLIONS) 67
CORTICOBASAL GANGLIONIC DEGENERATION 67
TABLE 23 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC
DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68
FIGURE 14 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC
DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68
MARKET BY TECHNOLOGY 68
SMALL MOLECULES 69
MONOCLONAL ANTIBODIES 70
OTHERS 70
Stem Cells 70
Biomarkers 71
MARKET OVERVIEW 72
MARKET REVENUE 73
TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017 ($
MILLIONS)
73
FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 74
MARKET SHARE 74
TABLE 25 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74
FIGURE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74
INDUSTRY STRUCTURE 75
LEADING MANUFACTURERS OF DRUGS USED TO TREAT HUNTINGTON’S
DISEASE 75
TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT
HUNTINGTONâ??S DISEASE 75
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT
HUNTINGTON’S DISEASE 78
TABLE 27 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO
TREAT HUNTINGTON'S DISEASE, 2011 (%) 78
FIGURE 17 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR
USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%) 79
LEADING MANUFACTURERS OF DRUGS USED TO TREAT CORTICOBASAL
GANGLIONIC DEGENERATION 79
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT
HUNTINGTON'S DISEASE 79
MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT
CORTICOBASAL GANGLIONIC DEGENERATION 81
TABLE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO
TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81
FIGURE 18 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT
CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81
CHAPTER 8 PATENT ANALYSIS 84
PATENTS ISSUED BY YEAR 84
TABLE 30 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.) 85
FIGURE 19 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.) 85
FIGURE 20 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%) 86
PATENTS BY DISEASE CATEGORY 86
TABLE 31 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86
FIGURE 21 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86
PATENTS BY DISEASE TYPE 87
SYNDROMES OF DEMENTIA 87
TABLE 32 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012
(NO.)
87
FIGURE 22 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY
CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.) 88
MOVEMENT DISORDER SYNDROMES 88
TABLE 33 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY DISEASE TYPE, 2010-MARCH 2012 (NO.) 89
FIGURE 23 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY DISEASE TYPE, 2010-MARCH 2012 (NO.) 89
PATENTS BY COUNTRY 89
SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) 89
TABLE 34 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 90
FIGURE 24 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 91
TABLE 35 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY
PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 91
MOVEMENT DISORDER SYNDROMES 92
TABLE 36 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 92
FIGURE 25 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 93
TABLE 37 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 94
PATENTS BY COMPANY 94
SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) 94
TABLE 38 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.) 96
MOVEMENT DISORDER SYNDROMES 100
TABLE 39 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY COMPANY, 2010-MARCH 2012 (NO.) 101
CHAPTER 9 CURRENT SITUATION 105
MARKET TRENDS 105
SYNDROMES OF DEMENTIA 105
Market Drivers 106
MOVEMENT DISORDER SYNDROMES 107
Market Drivers 108
OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS 108
OTHER FACTORS AFFECTING THE MARKET 109
COLLABORATIONS/MERGERS AND ACQUISITIONS 109
CHAPTER 10 COMPANY PROFILES 113
ABBOTT LABORATORIES 113
ABLYNX NV 113
ACCERA INC. 114
ACORDA THERAPEUTICS INC. 115
ACTAVIS ELIZABETH 115
AFFIRIS AG 116
ALLIANCE PHARMA PLC 116
ALLON THERAPEUTICS INC. 116
ALPHAPHARM 117
ALZHYME LTD. 117
AMERICAN REGENT INC. 118
APOTEX INC. 118
APOTHECA INC. 119
ASTELLAS PHARMA INC. 119
ASTRAZENECA GMBH 120
AUROBINDO PHARMA LTD. 120
BAXTER INTERNATIONAL INC. 121
BELLUS HEALTH INC. 121
BOEHRINGER INGELHEIM LTD. 122
BRISTOL-MYERS SQUIBB 123
BRYANT RANCH PREPACK 123
CADILA HEALTHCARE LTD. 124
CARACO PHARMACEUTICAL LABORATORIES 124
CARDINAL HEALTH 125
CELLZOME AG 125
CIPLA LTD. 126
COGNITION THERAPEUTICS INC. 126
COLUCID PHARMACEUTICALS INC. 126
COMENTIS INC. 127
CORTEX PHARMACEUTICALS 127
CYTOS BIOTECHNOLOGY AG 128
DAIICHI SANKYO CO. LTD. 128
DR. REDDY'S LABORATORIES LTD. 129
EISAI CO. LTD. 129
ELAN PHARMA INTERNATIONAL LTD. 130
ELI LILLY AND CO. 130
ENDO PHARMACEUTICALS INC. 131
ENVIVO PHARMACEUTICALS 132
EVOTEC AG 132
EPITOMICS INC. 133
EXONHIT THERAPEUTICS SA 133
FOREST LABORATORIES INC. 134
GLAXOSMITHKLINE PLC 134
GLENMARK GENERICS LTD. 135
H. LUNDBECK A/S 136
HAMELN PHARMACEUTICALS LTD. 137
HELICON THERAPEUTICS INC. 137
HOSPIRA INC. 137
INTELLECT NEUROSCIENCES INC. 138
INTRA-CELLULAR THERAPIES INC. 138
JAZZ PHARMACEUTICALS PLC 139
MAJOR PHARMACEUTICALS 139
MEDIVATION INC. 140
MEMORY PHARMACEUTICALS CORP. 140
MERCK SERONO 140
MERCK SHARP & DOHME LTD. 141
MERZ PHARMA GMBH & CO KGAA 141
MITHRIDION INC. 142
MYLAN PHARMACEUTICALS 142
NEUREN PHARMACEUTICALS LTD. 143
NEURO-HITECH INC. 144
NEUROPTIX CORP. 144
NEUROSEARCH A/S 145
NEWRON PHARMACEUTICALS SPA 146
NOSCIRA SA 146
NOVARTIS AG 147
NYMOX PHARMACEUTICAL CORP. 147
ORCHID CHEMICALS & PHARMACEUTICALS LTD. 148
ORION CORP. 148
ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC. 149
PAR PHARMACEUTICALS 149
PERRIGO CO. 150
PFIZER INC. 150
PHARNEXT 151
PHYSICIANS TOTAL CARE INC. 152
PLIVA HRVATSKA D.O.O. 152
PRASCO LABORATORIES 153
RANBAXY LABORATORIES LTD. 153
ROCHE HOLDING LTD. 154
ROXANE LABORATORIES INC. 154
SANDOZ INTERNATIONAL GMBH 155
SANOFI 155
SANTHERA PHARMACEUTICALS 156
SHIONOGI & CO. 157
STADA ARZNEIMITTEL AG 157
SUN PHARMA 158
TAJ PHARMACEUTICALS LTD. 158
TAKEDA PHARMACEUTICAL CO. LTD. 159
TERCICA INC. 160
TEVA PHARMACEUTICAL INDUSTRIES LTD. 160
TORRENT PHARMA 161
UCB SA 162
UDL LABORATORIES 162
UPSHER-SMITH LABORATORIES 163
VALEANT PHARMACEUTICALS 163
VERNALIS PLC 164
WATSON PHARMACEUTICALS INC. 164
WEST-WARD PHARMACEUTICAL 165
CHAPTER 11 APPENDIX I: ABBREVIATIONS 168
LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 6
TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY
PRIMARY CLINICAL/PATHOLOGICAL FEATURE 11
TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012 20
TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS 22
TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012 22
TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, 2010 TO MARCH 2012 23
TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, 2012 25
TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, 2011 30
TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, 2010 39
TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS) 46
TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT
NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47
TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR
NEURODEGENERATIVE DISORDERS, THROUGH 2017 ($ MILLIONS) 50
TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%) 51
TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 ($ MILLIONS) 53
TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54
TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 56
TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57
TABLE 17 CHDI FOUNDATIONS' KEY DEVELOPMENTS IN TREATING HUNTINGTON'S
DISEASE 61
TABLE 18 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017 ($
MILLIONS)
62
TABLE 19 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63
TABLE 20 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017 ($ MILLIONS) 65
TABLE 21 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66
TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE BY
REGION, THROUGH 2017 ($ MILLIONS) 67
TABLE 23 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC
DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68
TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017 ($
MILLIONS)
73
TABLE 25 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74
TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT
HUNTINGTONâ??S DISEASE 75
TABLE 27 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO
TREAT HUNTINGTON'S DISEASE, 2011 (%) 78
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT
HUNTINGTON'S DISEASE 79
TABLE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO
TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81
TABLE 30 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.) 85
TABLE 31 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86
TABLE 32 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012 (NO.) 87
TABLE 33 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY
DISEASE TYPE, 2010-MARCH 2012 (NO.) 89
TABLE 34 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 90
TABLE 35 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY
PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 91
TABLE 36 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY
PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 92
TABLE 37 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (%) 94
TABLE 38 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.) 96
TABLE 39 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY
COMPANY, 2010-MARCH 2012 (NO.) 101
LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 6
FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS) 47
FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT
NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%) 47
FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR
NEURODEGENERATIVE DISORDERS, 2010-2017 ($ MILLIONS) 50
FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%) 52
FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS BY REGION, 2010-2017 ($ MILLIONS) 53
FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%) 54
FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 56
FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%) 57
FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017 ($
MILLIONS)
63
FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%) 63
FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017 ($ MILLIONS) 65
FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%) 66
FIGURE 13 GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE BY REGION,
2010-2017 ($ MILLIONS) 67
FIGURE 14 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC
DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS) 68
FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA
WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017 ($ MILLIONS) 74
FIGURE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%) 74
FIGURE 17 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR
USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%) 79
FIGURE 18 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT
CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%) 81
FIGURE 19 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.) 85
FIGURE 20 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%) 86
FIGURE 21 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.) 86
FIGURE 22 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY
CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.) 88
FIGURE 23 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY DISEASE TYPE, 2010-MARCH 2012 (NO.) 89
FIGURE 24 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 91
FIGURE 25 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012 (NO.) 93
To order this report:
Pathology Industry: Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Progressive Dementia with Other Neurological Abnormalities
__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article